Clinical trial Recruiting at 1 site Observational Ages 19 and up Women only

Analyzing radiation therapy outcomes in HER2 positive breast cancer

Official title: Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer

Run by Samsung Medical Center · NCT05893966 · Data updated 2026-11-12

This study looks at how well radiation therapy works for women with HER2 positive breast cancer after they have had surgery, to see if it helps prevent cancer from coming back and to track any side effects over seven years.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages19 Years and up
SexWomen only
Enrollment400 (estimated)
SponsorSamsung Medical Center
Academic / other
Drugs / interventionsradiation
Locations1 site (Seoul, Seoul)
StatusRecruiting
StartedNovember 29, 2022
Main results expectedNovember 29, 2030
Study endsNovember 29, 2032
Registry record updatedAugust 10, 2026
Trial IDNCT05893966 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are female patients aged 19 and older with confirmed HER2 positive invasive breast cancer who have undergone breast conserving surgery.

Probably not a fit

Patients with ductal carcinoma in situ or those who have previously received radiation therapy to the ipsilateral breast may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on evaluating the treatment outcomes of postoperative radiation therapy, specifically the tumor bed boost, in female patients with HER2 positive breast cancer who have undergone breast conserving surgery. The study aims to assess various outcomes over a seven-year period, including ipsilateral breast tumor recurrence, disease-free survival, locoregional recurrence, overall survival, and adverse events related to radiation therapy. Participants will undergo multi-dimensional assessments to monitor their disease status and any side effects from the treatment.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into optimizing radiation therapy for HER2 positive breast cancer, potentially improving patient outcomes.

How similar studies have gone: While there have been studies on radiation therapy in breast cancer, this specific focus on tumor bed boost in HER2 positive patients is relatively novel and not extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female patients with age minimum 19
* Pathological confirmation of HER2+ invasive breast cancer
* Eastern Cooperative Oncology Group performance status 0-2
* Informed consent of the participant

Exclusion Criteria:

* Pathological confirmation of ductal carcinoma in situ of the breast
* Previous history of radiation therapy to ipsilateral breast

Where it's running

  • Samsung Medical Center
    Seoul, Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.